pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,545 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165BioSpace64Fierce Biotech64raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Opinion: American horses are obese, too
    “American horses are getting sick in ways that look remarkably familiar,” writes Joshua Moen.
    STAT · 1mo ago↗ source
  • Opinion: $2 million gene therapy cures require a financing model
    “We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
    STAT · 1mo ago↗ source
  • STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
    STAT · 1mo ago↗ source
← prev
page 29 of 62
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
    Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE…
    Endpoints · 1mo ago↗ source
  • STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
    Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
    STAT · 1mo ago↗ source
  • STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
    Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
    STAT · 1mo ago↗ source
  • #ADA26: Pfizer's monthly shot shows effect on obesity, diabetes
    The long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according to data presented Saturday.…
    Endpoints · 1mo ago↗ source
  • STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
    Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
    STAT · 1mo ago↗ source
  • #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
    Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…
    Endpoints · 1mo ago↗ source
  • Lawmakers propose China restrictions; #ASCO26 recap; and more
    Welcome back to Endpoints Weekly! We had a small team in Chicago last weekend at this year’s ASCO conference. You’ll find a recap of their coverage below, including more details on Revolution Medic…
    Endpoints · 1mo ago↗ source
  • Opinion: How the Amish think about vaccines, health care costs, and much more
    There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
    STAT · 1mo ago↗ source
  • Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
    “Ebola is an unforgiving enemy,” writes Tom Frieden, who led the U.S. CDC response to the 2014-2016 Ebola outbreak.
    STAT · 1mo ago↗ source
  • #ADA26: Roche's incretin shot works in mid-stage trial in type 1 diabetes
    A daily incretin shot being developed by Roche has shown promise in type 1 diabetes — the form that is not generally believed to be directly treatable by GLP-1-based drugs. According to Phase 2 d…
    Endpoints · 1mo ago↗ source
  • CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
    The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread, according to a new U.S. analysis.
    STAT · 1mo ago↗ source
  • STAT+: Newer GLP-1s, pushback on research cuts, and a protest
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
    Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired.
    STAT · 1mo ago↗ source
  • Senior NIH official pushes MAHA strategy to skeptical ADA audience
    An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.
    STAT · 1mo ago↗ source
  • In Washington, biotech's China hawks are winning the conversation
    Biopharma industry lobby groups working to keep the pipeline open for plentiful, lower-cost drugs coming from China have awakened to the fact that they face a vocal opposition and a growing set of…
    Endpoints · 1mo ago↗ source
  • Industry seeks more clarity on commissioner's voucher program
    The pharma industry and rare disease advocates voiced concerns about the transparency and fairness of the Commissioner's National Priority Voucher pilot program. The program faces an uncertain fu…
    Endpoints · 1mo ago↗ source
  • House committee directs FDA to speed up IND sign-off process
    The House Appropriations Committee told the FDA to reform the way it signs off on new clinical trials, reflecting a broader effort to ensure the US keeps pace with China and other nations in develo…
    Endpoints · 1mo ago↗ source
  • Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
    Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win wi…
    Endpoints · 1mo ago↗ source
  • Opinion: If Americans risk their lives fighting Ebola overseas, they deserve the right to come home
    Outbreak response is difficult enough without asking responders to wonder whether they will have access to the best available care if they become ill.
    STAT · 1mo ago↗ source
  • STAT+: Will Makary’s FDA voucher program survive?
    RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
    STAT · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source